Patents by Inventor Mohamed B. Ezzelarab

Mohamed B. Ezzelarab has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF EOMESODERMIN TO DETERMINE RISK OF ALLOGRAFT REJECTION
    Publication number: 20210263013
    Abstract: Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to modify immunosuppressive therapy.
    Type: Application
    Filed: April 30, 2021
    Publication date: August 26, 2021
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Mohamed B. Ezzelarab, Angus W. Thomson
  • Use of Eomesodermin to determine risk of allograft rejection
    Patent number: 11022601
    Abstract: Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to modify immunosuppressive therapy.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: June 1, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Mohamed B. Ezzelarab, Angus W. Thomson
  • USE OF EOMESODERMIN TO DETERMINE RISK OF ALLOGRAFT REJECTION
    Publication number: 20180045710
    Abstract: Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to modify immunosuppressive therapy.
    Type: Application
    Filed: January 22, 2016
    Publication date: February 15, 2018
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Mohamed B. Ezzelarab, Angus W. Thomson